The research is being carried out by the Academy of Military Medical Sciences, affiliated with the Chinese Army, which received the green light to launch this week’s phase 1 clinical trial.
This Chinese test targets 108 volunteers, all healthy, and runs throughout nine and a half months, from March 16 to December 31, shows the registration database for the test.
The test is carried out by the Academy of Military Medical Sciences in collaboration with CanSino Biologics, a company active in the field of biotechnology in Hong Kong.
Further research is underway in the world.
In the United States, the American National Institute of Allergy and Infectious Diseases (NIAID) announced on Monday the launch of a clinical trial in Seattle, together with the Modern Biotechnology group, to be performed on a cohort of 45 adult volunteers with foals. between 18 and 55 years for six weeks
The German CureVac laboratory also hopes to be able to apply for authorization to go through the clinical testing phase of an experimental vaccine on humans by July.
Experts from the World Health Organization (WHO) do not expect a vaccine to be tested or approved for commercialization early next year.